Ticker Details
ADMA Biologics Inc ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases.
IPO Date:	October 18, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.31B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.17 | 2.74%
Avg Daily Range (30 D):	$0.44 | 3.44%
Avg Daily Range (90 D):	$0.39 | 2.51%

Institutional Daily Volume
Avg Daily Volume:	1.7M
Avg Daily Volume (30 D):	6.87M
Avg Daily Volume (90 D):	3.62M

Trade Size
Avg Trade Size (Sh.):	174
Avg Trade Size (Sh.) (30 D):	116
Avg Trade Size (Sh.) (90 D):	101

Institutional Trades
Total Institutional Trades:	2,272
Avg Institutional Trade:	$3.43M
Avg Institutional Trade (30 D):	$3.7M
Avg Institutional Trade (90 D):	$3.54M
Avg Institutional Trade Volume:	.3M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.77M
Avg Closing Trade (30 D):	$10.05M
Avg Closing Trade (90 D):	$8.15M
Avg Closing Volume:	508.34K

News

Apr 10, 2026 @ 7:48 PM ADMA Biologics (NASDAQ: ADMA) Investigated for Pot... Source: Lowey Dannenberg, P.C.

Apr 8, 2026 @ 8:57 PM Bragar Eagel & Squire, P.C. Urges ADMA Biologics, ... Source: Bragar Eagel & Squire, P.C.

Apr 7, 2026 @ 8:59 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: Pomerantz Llp

Apr 3, 2026 @ 10:46 AM $ADMA Stock News: ADMA Biologics Investigated for ... Source: Bleichmar Fonti & Auld Llp

Mar 31, 2026 @ 10:00 PM ADMA SHAREHOLDER ALERT: Investors Encouraged to Co... Source: Kirby Mcinerney Llp

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$.62	$.21	$.62
Diluted EPS	$.6	$.2	$.6
Revenue	$510.17M	$139.16M	$510.17M
Gross Profit	$292.77M	$88.82M	$292.77M
Net Income / Loss	$146.93M	$49.38M	$146.93M
Operating Income / Loss	$191.44M	$62.75M	$191.44M
Cost of Revenue	$217.41M	$50.35M	$217.41M
Net Cash Flow	$-15.52M	$26.25M	$-15.52M
PE Ratio	17.57